Clinician’s Perspectives on the Role of Rosuvastatin and Its Combinations for Managing Dyslipidemia in Indian Settings
Manjula S *
Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India.
Krishna Kumar M
Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India.
*Author to whom correspondence should be addressed.
Abstract
Objective: To evaluate clinicians' perspectives on dyslipidaemia management in Indian settings, specifically focusing on the use of rosuvastatin and its combinations.
Methods: A cross-sectional study was conducted among clinicians across India, focusing on hypertension management and the use of rosuvastatin and its combinations. Participants independently completed a 23-item questionnaire after giving informed consent. The data was analyzed using descriptive statistics, with categorical variables expressed as percentages and visualized through pie and bar charts in Excel.
Results: Approximately 68% of participants indicated that dyslipidaemia is more prevalent in the urban population. Over half (57.64%) of the clinicians reported that high-risk patients with atherosclerotic cardiovascular disease (ASCVD) prefer high-dose statins. Nearly all (95.22%) participants preferred rosuvastatin as the statin of choice for dyslipidaemia patients. A majority (75.8%) of the participants commonly prescribed a 10 mg daily dose of rosuvastatin for dyslipidaemia. Around 67% of the clinicians stated that rosuvastatin is used for both primary and secondary prevention of cardiovascular events. About 76% of the participants preferred combining fibrates and statins for treating dyslipidaemia. Around 63% of the respondents reported that 11-20% of patients are prescribed the rosuvastatin and fenofibrate combination, while 66.4% of the participants indicated frequent use of the fixed-dose combination of rosuvastatin, clopidogrel, and aspirin in clinical practice.
Conclusion: The study highlights the clinical management of dyslipidaemia in high cardiovascular risk populations, emphasizing rosuvastatin use, often combined with fibrates or antiplatelet agents. It underscores rosuvastatin's role in both primary and secondary prevention of cardiovascular events, while suggesting that lifestyle factors and comorbidities, like diabetes, should guide treatment.
Keywords: Dyslipidaemia, cardiovascular disease, statins, rosuvastatin, fenofibrate, dual antiplatelet therapy